Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based conditioning regimens designed to enable safer and more effective hematopoietic stem cell transplantation (HSCT). The company operates within the biopharmaceutical and biotechnology industries, with a strategic emphasis on rare diseases, immune disorders, and oncology-adjacent transplant applications. Its approach seeks to replace or reduce the need for toxic chemotherapy or radiation traditionally used in transplant conditioning.

The company’s primary asset and revenue driver is briquilimab (formerly JSP191), a monoclonal antibody targeting c-Kit (CD117), which plays a key role in stem cell survival. Jasper Therapeutics does not currently generate product revenue and is primarily funded through equity financing. The company was formed to advance technology licensed from academic research and became publicly traded in 2021 through a merger with a special purpose acquisition company. Its strategy centers on applying a single targeted conditioning platform across multiple transplant-enabled disease areas.

Business Operations

Jasper Therapeutics operates as a single operating segment biotechnology company, with activities concentrated on research and development, clinical trials, regulatory engagement, and corporate operations. Its core business is the development of briquilimab, which is being evaluated across multiple clinical programs including severe combined immunodeficiency (SCID), other inborn errors of immunity, and selected hematologic malignancy and transplant-adjacent indications.

Operations are primarily conducted in the United States, with clinical trials carried out through third-party clinical research organizations and academic medical centers. The company does not own manufacturing facilities and relies on external contract manufacturing organizations for drug substance and drug product. Jasper Therapeutics holds exclusive rights to its core antibody technology and does not report material joint ventures or revenue-generating subsidiaries. Public disclosures indicate that substantially all operating expenses relate to R&D and general corporate costs.

Strategic Position & Investments

Jasper Therapeutics’ strategic direction is focused on establishing antibody-based conditioning as a new therapeutic category that may broaden access to curative stem cell transplants. Growth initiatives are centered on advancing briquilimab through mid-stage clinical development and expanding its potential use across multiple transplant settings where reduced-toxicity conditioning is clinically desirable.

The company has made targeted investments in clinical development rather than acquisitions, and public filings do not indicate completed material acquisitions of other companies. Its intellectual property portfolio is built around licensed academic discoveries and internally developed know-how related to CD117 targeting. Jasper Therapeutics positions itself as a first mover in this niche, though management acknowledges that competing approaches, including gene therapy-enabled conditioning strategies, are emerging. No diversification into unrelated therapeutic areas has been disclosed.

Geographic Footprint

Jasper Therapeutics is headquartered in Redwood City, California, and its operations are primarily based in the United States. Corporate leadership, research oversight, and regulatory activities are conducted domestically, with clinical trials taking place at U.S.-based medical centers and hospitals specializing in transplant medicine.

While the company does not maintain significant international offices, its clinical programs are designed to support future regulatory filings that could enable broader North American and international market participation. Any global reach at present is indirect, occurring through internationally sourced manufacturing partners and globally recognized academic collaborators rather than owned foreign operations.

Leadership & Governance

Jasper Therapeutics is led by an executive team with experience in biotechnology development, capital markets, and rare disease drug commercialization. The leadership emphasizes a strategy centered on scientific rigor, capital discipline, and focused clinical execution in narrowly defined patient populations.

Key executives include:

• Ronald A. Martell – President and Chief Executive Officer
• Kevin O’Donnell – Chief Financial Officer
• Ann Woolley – Chief Medical Officer
• David Horn Solomon – Chair of the Board of Directors

Public disclosures consistently identify these individuals as responsible for corporate strategy, financial oversight, and clinical development. Any additional executive appointments or recent changes beyond these roles are data inconclusive based on available public sources.